Irvine, California – July 8, 2026. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced today that it has acquired iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company.
The deal brings Tarsus the rights to IRX-101, an investigational ocular antiseptic designed to reduce post-procedural pain and corneal toxicity in patients undergoing intravitreal injections.
Tarsus completed the merger on July 6, 2026, and disclosed the transaction publicly two days later.
What The Deal Covers?
IRX-101 is a stable aqueous chlorine dioxide solution. In a completed Phase 2b/3 trial, it produced statistically significant reductions in post-procedural pain and corneal fluorescein staining, a standard measure of corneal surface damage, when compared against povidone-iodine, the antiseptic marketed as Betadine and currently used in most intravitreal procedures.
The Problem IRX-101 Aims To Solve
More than 11 million intravitreal injections take place in the U.S. each year, and povidone-iodine remains the default antiseptic for nearly all of them. For many patients, that comes with a cost: corneal surface toxicity that can cause pain lasting for days after treatment.
Povidone-iodine is also unsuitable for patients with iodine sensitivity, and despite these limitations, no new ocular antiseptic has reached FDA approval in more than 40 years.
The burden compounds for patients with chronic retinal conditions, including neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion-related macular edema, and geographic atrophy.
These patients often need intravitreal injections as frequently as every four weeks to protect their vision, meaning any pain or irritation tied to the antiseptic recurs with every visit.
That recurring discomfort can affect whether patients keep up with their treatment schedule, which in turn affects long-term outcomes.
Trial Results Behind The Acquisition
The Phase 2b/3 RELIEF trial enrolled 154 patients and tested IRX-101 against povidone-iodine on two co-primary endpoints.
Patients receiving IRX-101 reported roughly a 50% relative reduction in post-procedural pain scores (p=0.0003), and half of that group reported no pain at all.
Corneal fluorescein staining dropped by approximately 25% relative to the povidone-iodine group (p=0.0003), indicating less surface damage to the cornea.
What Comes Next?
Tarsus has aligned its next steps with FDA feedback and plans to launch a Phase 3 study comparing IRX-101’s tolerability and safety against povidone-iodine. Enrollment is expected to begin in the first half of 2027, with results anticipated in 2028.
Deal Structure
Tarsus paid iRenix equityholders $37.5 million in cash and issued 607,093 shares of Tarsus common stock as upfront consideration, together valued at approximately $75 million.
iRenix equityholders stand to receive up to $490 million in additional payments tied to regulatory and commercial milestones, along with low-to-mid single-digit royalties on certain future net sales.
What Company Leadership Is Saying?
Bobby Azamian, Tarsus’s CEO and Chairman, pointed to the company’s experience with XDEMVY as evidence that meaningful innovation in overlooked areas of eye care can make a real difference for patients.
He said IRX-101 has the potential to bring similar benefits to patients with retinal disease who depend on repeated procedures, and that reducing the pain and toxicity tied to current antiseptic options could benefit both patients and the physicians who treat them while giving Tarsus a foothold in retina care.
David Brown, Chief Medical Officer at Retina Consultants of America, said retina specialists have stuck with the same antiseptic approach for decades not because it works well, but because no better option has existed.
He said patients frequently describe the burning and irritation after treatment as one of the hardest parts of repeated injections, and that the data so far suggest IRX-101 could ease that experience without sacrificing antiseptic effectiveness.
Stephen Smith, CEO and co-founder of iRenix Medical, said IRX-101 was built specifically to improve the experience of patients undergoing repeated retinal procedures. He said he takes pride in how far the iRenix team advanced the program, and that Tarsus’s track record in identifying and addressing overlooked needs in eye care gives him confidence in the program’s future.
Investor Call
Tarsus will hold a live conference call and webcast today, July 8, 2026, at 1:30 p.m. PT / 4:30 p.m. ET, to discuss the acquisition. The webcast will be available through the Investor Relations section of the Tarsus website, with a replay posted for at least 90 days afterward.
About Tarsus Pharmaceuticals
Tarsus develops treatments across eye care, dermatology, and infectious disease prevention. Its approved product, XDEMVY (lotilaner ophthalmic solution) 0.25%, treats Demodex blepharitis in the U.S. The company’s pipeline also includes TP-04, in Phase 2 development for ocular rosacea, and TP-05, an oral tablet in Phase 2 development for Lyme disease prevention.